Abstracts tagged "antibodies and rheumatoid arthritis (RA)"

Abstract Number: 1325 • 2017 ACR/ARHP Annual Meeting
Immune Responses to Peptides Containing Homocitrulline or Citrulline in the DR4-Transgenic Mouse Model of Rheumatoid Arthritis
Patrick Lac¹, Sheri Saunders¹, Elena Tutunea-Fatan¹, Lillian Barra², David Bell³ and Ewa Cairns², ¹Microbiology and Immunology, The University of Western Ontario, London, ON, Canada, ²Medicine, Microbiology and Immunology, The University of Western Ontario, London, ON, Canada, ³Medicine, The University of Western Ontario, London, ON, Canada
Background/Purpose: Antibodies to proteins/peptides containing citrulline (commonly measured using cyclic citrullinated peptide, CCP2) are hallmarks of Rheumatoid Arthritis (RA). These antibodies are strongly associated with…
Abstract Number: 1547 • 2016 ACR/ARHP Annual Meeting
Antibodies Against Carbamylated Proteins in Belgian RA Patients and in Other Rheumatic Diseases
Paschalis Sidiras¹, Celine La¹, Bernard R. Lauwerys², Patrick Durez², Delphine Spruyt³, Joanne Rasschaert³, Tatiana Sokolova⁴, Laurent Meric de Bellefon⁵, Sandra Kleimberg¹, Laure Tant¹, Muhammad Soyfoo¹ and Valérie Badot¹, ¹Rheumatology, Hôpital Erasme,Université Libre de Bruxelles, Brussels, Belgium, ²Pôle de pathologies rhumatismales inflammatoires et systémiques, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, ³Laboratory of Bone and Metabolic Biochemistry, Université Libre de Bruxelles, Brussels, Belgium, ⁴Project Coordinator, CAP 48 cohort, Brussels, Belgium, ⁵Rheumatology, Cliniques Universitaires Saint-Luc, CHU Saint-Pierre Brussels, Clinique Notre-Dame de Grâce, Gosselies, Brussels, Belgium
Background/Purpose: Antibodies targeting carbamylated proteins (Anti-CarP) have been recently described in Rheumatoid Arthritis (RA) and are reported to be associated with increased disease activity and…
Abstract Number: 2616 • 2015 ACR/ARHP Annual Meeting
Study of Anti-Carbamylated Protein Antibody in the Rheumatoid Patients Who Were Clinically Active and Under Treatment with Biological Dmards
Kazuko Shiozawa¹ and Shunichi Shiozawa², ¹Rheumatic Diseases Center, Konan Kakogawa Hospital, Kakogawa, Japan, ²Department of Medicine, Rheumatic Diseases Unit, Kyushu University Beppu Hospital, Beppu, Japan
Background/Purpose: A newly discovered anti-carbamylated protein antibody (anti-CarP) is found prior to disease-onset, associates with the conversion towards arthralgia and with a more severe disease…
Abstract Number: 2734 • 2015 ACR/ARHP Annual Meeting
Validation and Comparison Study of Immunoassays for the Measurement of Golimumab and Antibodies to Golimumab in Rheumatic Patients
Sergio Martín^1,2, Ainhoa Ruiz del Agua¹, Nerea Torres¹, Dora Pascual-Salcedo³, Chamaida Plasencia⁴, Teresa Jurado⁵, Begoña Ruiz-Argüello¹, Antonio Martínez¹, Rosaura Navarro⁶ and Daniel Nagore¹, ¹R&D, Progenika-Grifols, Derio, Spain, ²Department of Physiology, Medicine and Dentistry School, University of the Basque Country UPV/EHU (Convocatoria ZabaldUZ, UPV/EHU; Departamento de Educación, Universidades e Investigación del Gobierno Vasco, Ref. IT687-13), Leioa, Spain, ³Immunology Unit, La Paz University Hospital-Immunology, Madrid, Spain, ⁴Rheumatology Unit, La Paz University Hospital-Rheumatology, Madrid, Spain, ⁵Immunology, La Paz University Hospital-Idipaz, Madrid, Spain, ⁶Department of Physiology, Medicine and Dentistry School, University of the Basque Country UPV/EHU, Leioa, Spain
Background/Purpose: The options for treatment of rheumatoid arthritis (RA) with tumour necrosis factor (TNF) inhibitors is constantly growing. As a consequence monitoring of drug levels (DL)…
Abstract Number: 447 • 2014 ACR/ARHP Annual Meeting
Rheumatoid Factor Isotypes in Relation to Antibodies Against Citrullinated Peptides in Individuals before Onset of Rheumatoid Arthritis
Mikael Brink¹, Monika Hansson², Linda Mathsson-Alm³, Johan Rönnelid³, Lars Klareskog² and Solbritt Rantapää-Dahlqvist⁴, ¹Public Health & Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden, ²Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden, ³Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden, ⁴Public Health & Clinical Medicine/Rheumatology, Institution of Public health and clinical medicine/ Rheumatology, University of Umeå, Rheumatology, Sweden, Umeå, Sweden
Background/Purpose The presence of rheumatoid factor (RF) and antibodies against citrullinated peptides (ACPA) has been shown to precede the development of rheumatoid arthritis (RA) by…
Abstract Number: L21 • 2014 ACR/ARHP Annual Meeting
Striking Discrepancy in the Development of Anti-Drug Antibodies (ADA) in Patients with Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS) in Response to Infliximab (INF) and Its Biosimilar CT-P13
Jürgen Braun¹, Xenofon Baraliakos¹, Alex Kudrin², H. Kim³ and Sang Joon Lee², ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²CELLTRION, Inc., Incheon, South Korea, ³CELLTRION, Inc, Incheon, Republic of Korea, Incheon, South Korea
Background/Purpose: The differences between RA and AS have been recently highlighted (1). There is evidence that there are major clinical, pathophysiological and genetic differences. In…
Abstract Number: 2430 • 2013 ACR/ARHP Annual Meeting
Antibodies To Porphyromonas Gingivalis as An Etiological Clue To The Development Of Anti-Citrullinated Protein Antibody Positive Rheumatoid Arthritis
Nastya Kharlamova¹, Natalia Sherina¹, Anne-Marie Quirke², Kaja Eriksson³, Lena Israelsson⁴, Jan Potempa⁵, Patrick Venables⁶, Tulay Yucel-Lindberg³ and Karin Lundberg⁷, ¹Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ²University of Oxford, Kennedy Institute of Rheumatology, Oxford, United Kingdom, ³Department of Dentistry, Karolinska Institutet, Stockholm, Sweden, ⁴Medicine, Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, ⁵Microbiology Department, Jagiellonian University, Krakow, Poland, ⁶Kennedy Institute of Rheumatology, Oxford, United Kingdom, ⁷Rheumatology unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Rheumatoid arthritis (RA) is characterized by the production of autoantibodies to citrullinated proteins (ACPA). Citrullinated proteins are generated by the actions of peptidyl arginine…
Abstract Number: 2409 • 2013 ACR/ARHP Annual Meeting
Association Of High Serum Interleukin-23 Levels With Porphyromonas Gingivalis Antibodies In Patients With Early Rheumatoid Arthritis
Sheila L. Arvikar¹, Klemen Strle², Deborah S. Collier³, Mark C. Fisher¹, Toshihisa Kawai⁴, Jose U. Scher⁵ and Allen C. Steere⁶, ¹Rheumatology, Allergy & Immunology, Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, MA, ³Rheumatology, Massachusetts General Hospital, Boston, MA, ⁴Forsyth Institute, Cambridge, MA, ⁵Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁶Medicine, Center for Immunolgy and Inflammatory Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased frequency of periodontal disease (PD) and antibodies to P. gingivalis (Pg), a major periodontal pathogen. Both…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].